Morpholine → HCID 21254991, compound
Reaction equation
[NH:1]1[CH2:6][CH2:5][O:4][CH2:3][CH2:2]1.[C:7]1([S:13]([C:16]2[C:17]([CH2:33][CH3:34])=[N:18][N:19]3[C:24]([N:25]4[CH2:30][CH2:29][N:28]([CH3:31])[CH2:27][CH2:26]4)=[CH:23][C:22](Cl)=[N:21][C:20]=23)(=[O:15])=[O:14])[CH:12]=[CH:11][CH:10]=[CH:9][CH:8]=1>CN(C=O)C>[C:7]1([S:13]([C:16]2[C:17]([CH2:33][CH3:34])=[N:18][N:19]3[C:24]([N:25]4[CH2:26][CH2:27][N:28]([CH3:31])[CH2:29][CH2:30]4)=[CH:23][C:22]([N:1]4[CH2:6][CH2:5][O:4][CH2:3][CH2:2]4)=[N:21][C:20]=23)(=[O:14])=[O:15])[CH:12]=[CH:11][CH:10]=[CH:9][CH:8]=1Participants
4
Reactant 2
Product 1
Reagents, catalysts & solvents 1
Procedure
0.26 ml (3 mmol) of morpholine in 5 ml of DMF was added to a solution of 0.50 g (1.2 mmol) of 3-benzenesulphonyl-5-chloro-2-ethyl-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidine in 15 ml of DMF and stirred at 100° for hr. After cooling to RT the reaction solution was evaporated and the residue was partitioned between 2N NaOH and CH2Cl2. The aqueous phase was extracted three times with CH2Cl2, and the combined organic phases were dried (MgSO4), filtered and evaporated. Subsequent chromatography (SiO2, CH2Cl2/MeOH 15:1) and crystallization from EtOH yielded 0.45 g (80%) of 3-benzenesulphonyl-2-ethyl-7-(4-methyl-piperazin-1-yl)-5-morpholin-4-yl-pyrazolo[1,5-a]-pyrimidine as colorless crystals, m.p.>250°.
Workup
- customwas evaporated
- customthe residue was partitioned between 2N NaOH and CH2Cl2
- extractionThe aqueous phase was extracted three times with CH2Cl2
- dry with materialthe combined organic phases were dried (MgSO4)
- filtrationfiltered
- customevaporated
- customSubsequent chromatography (SiO2, CH2Cl2/MeOH 15:1) and crystallization from EtOH
Sources & evidence
- ORD record
- ord-244ad3cda33b495a8c0397ba6be27ac6
- Source dataset
- uspto-grants-2001_02
- Patent number
- US06194410B1
Reaction notes
Loading…